Andrew X. Zhu
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma(2020)6,907 cited
- → Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases(2018)4,515 cited
- → AASLD guidelines for the treatment of hepatocellular carcinoma(2017)4,115 cited
- → Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial(2018)2,497 cited
- → Hepatobiliary Cancers(2009)2,267 cited
- → Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer(2004)1,946 cited
- → Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial(2019)1,782 cited
- → Immunotherapies for hepatocellular carcinoma(2021)1,729 cited
- → Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma(2008)1,656 cited
- → Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)1,630 cited